• Founder’s Vision
  • ANKTIVA
  • BCG
  • Our Science
  • Careers
  • Contact
ImmunityBio
  • Patients & Caregivers
    • ANKTIVA®
    • Clinical Trials
    • Patients
    • Therapeutic Areas
      • Bladder Cancer
      • Glioblastoma
      • HIV
      • Human Papillomavirus
      • Lymphopenia
      • Lynch Syndrome
      • Non-Hodgkin Lymphoma
      • Non-Small Cell Lung Cancer
      • Ovarian Cancer
  • Healthcare Providers
    • ANKTIVA®
    • Clinical Trials
    • Trial Investigators
    • Expanded Access
  • Researchers
    • Platforms & Modalities
    • Trial Investigators
    • Cell Licensing
    • Publications
  • Our Company
    • About
    • Pipeline
    • Contact
    • Compliance & Transparency
  • News and Events
  • Investors
Select Page

ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.

Feb 1, 2018 | Uncategorized

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Feb 12, 2017 | Uncategorized

IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.

Feb 12, 2017 | Uncategorized

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Feb 12, 2017 | Uncategorized

The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Feb 12, 2016 | Uncategorized

« Older Entries
Next Entries »

Recent Posts

  • Piper Sandler 37th Annual Healthcare Conference
  • Jefferies Global Healthcare Conference in London
  • New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
  • Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
  • European Society For Medical Oncology (ESMO)
 

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  X
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2025 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

’ImmunityBio’, ‘ImmunityBio Care’, 'Anktiva’, ‘ThAnktiva’, ‘haNK’, ‘taNK’, ‘ceNK’, ‘NK-92’, ‘Nant Cancer Vaccine’, ‘NANT 001’, ‘NANT XL’, ‘NANT 001 and Design’, ‘QUILT’, ‘Outsmart Your Disease’, ‘Smart Therapies for Difficult Diseases’, ‘Nantkwest’, ‘VivaBioCell’, and ‘Infacell’ are trademarks or registered trademarks of ImmunityBio, Inc., its subsidiaries and affiliates.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap